You are here Home R & D Astron Research NDDS
NDDS

Intas R&D has also developed NDDS products and commercialized three pharmaceutical formulations, being the Nanosomal Tacrolimus injection, Nanosomal Amphotericin B injection and a Minoxidil + Finasteride lipid solution for the Indian market.

Our NDDS portfolio includes the following products including novel formulations for international markets:

  • Nanosomal Docetexal Injections: Formulation development has been completed, validation batches have been taken and ICH stability studies are underway. The phase II efficacy studies, approved by the DCGI, in relation to breast cancer patients have been completed in India
  • Nanosomal Paclitexal Injections: Formulation development has been completed, validation batches have been taken and ICH stability studies are underway. The phase II efficacy studies, approved by the DCGI, in relation to breast cancer patients have been completed in India
  • Cabazitaxel Lipid Suspension: Astron is currently in the process of developing this formulation.